Milan, Italy Jan. 17, 2023
KLISBio to participate at 2023 AAHS, ASPN & ASRM Annual Meeting
Milan, Italy (January 16th, 2023) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2023 AAHS, ASPN & ASRM Annual Meeting. The event will be held January 17 - 22, 2023 in Miami – FL. Gabriella Francavilla, Global Marketing Manager, will be attending the congress with the aim to cement current relationships and establish new ones with physicians and strategic partners, in order to implement KLISBio Early Adopters Engagement Plan by starting preliminary conversations with Peripheral Nerve Repair surgeons.
KLISBio’s first product in pipeline is SILKBridge® Nerve Guide, a silk fibroin absorbable medical device for peripheral nerve repair. The promising results of the first clinical study on SILKBridge® Nerve Guide conducted by Prof. Maurizio Calcagni, Deputy Clinic Director at Department of Plastic Surgery and Hand Surgery at University Hospital Zurich, were previously presented at 2022 IFSSH, IFSHT & FESSH Combined Congress in London, UK and at SGH, SGHT Congress in Thun, Switz.
SILKBridge® Nerve Guide is a tissue-engineered technology made of pure silk fibroin. It has the potential to show an optimized balance between biomechanical and biological properties, complementing the high strength of native silk fibers and the enhanced biomimicry of electrospun silk. It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. KLISBio is working with a world-renowned panel of KOLs in hand surgery both in US and EU with the aim to make SILKBridge® Nerve Guide a competitive solution for Peripheral Nerve Repair.
“In the past year, we have been working with our panel of well-known US KOLs to design preclinical and clinical activities and gather all data needed to raise interest among the Peripheral Nerve Repair surgeons. It has been a very productive journey so far. We are now at the beginning of a new process to expand our relations and create a panel of Early Adopters with whom we would like to activate further dialogs, before implementing a complete and already-designed sales strategy, which will be soon discussed with potential Business Partners.”, said Gabriella Francavilla, Global Marketing Manager.
The multilayered silk-based structure of SILKBridge® Nerve Guide is developed to confer ideal porosity and compression resistance to the device to promote safe nerve regeneration and functional recovery, while showing an optimized degradation profile that allows the conduit to support the nerve throughout its healing process. The 3-D architecture of SILKBridge® Nerve Guide, with a combination of electrospun and textile layers, is specifically designed to confer an optimized balance between mechanical resistance and patient comfort and to promote cells ingrowth. The electrospun layers mimicking the morphology and dimensions of fibrous components of the extracellular matrix provide a range of biochemical, topographical and mechanical cues to enhance cellular interaction. The intermediate textile layer is an open-mesh structure, designed to confer high mechanical performance and resistance to the device, resorbing at slow rate. SILKBridge® Nerve Guide is not yet FDA cleared.
KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers. The Company is powered by a group of world leaders in MedTech including Gabriele Grecchi, CEO; Antonio Alessandrino, Chief Technology Officer and Giuliano Freddi, Chief Scientific Officer. KLISBio recently announced that Rodrigo Bianchi will serve as Chairman of the Board, joining the company with more than three decades of experience in global healthcare. In addition to its strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space.
KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.